Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific Officer
15 Februar 2005 - 6:01AM
PR Newswire (US)
Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific
Officer STRASBOURG, France, Feb. 15 /PRNewswire-FirstCall/ --
Transgene (Nasdaq: TRGNY; Euronext: FR0005175080) announced today
the appointment of Dr. Jean-Yves Bonnefoy as its new Chief
Scientific Officer. He replaces Serge Braun who has decided to
pursue other opportunities outside of the Company. Prior to joining
Transgene, Jean-Yves Bonnefoy, 45, was Head of the Canceropole Lyon
Rhones-Alpes. From 1997 to 2002, he was Director of the Immunology
Center of the Pierre Fabre Group in Saint-Julien en Genevois,
France. He previously was responsible for the Immunology Department
of the Biomedical Research Institute of the Glaxo-Wellcome Group in
Geneva, Switzerland. Jean-Yves Bonnefoy holds a PhD in immunology
from the Lyons Claude Bernard University and has completed the
Senior Management Program of the London Business School. "We thank
Serge Braun for his contribution to the development of Transgene,"
stated Philippe Archinard, Chief Executive Officer of Transgene.
"We are delighted to integrate Jean-Yves' immunology experience and
background in the infectiology and oncology fields. His arrival
will allow us to reinforce Transgene as a company dedicated to
therapeutic vaccination." About Transgene Transgene, based in
Strasbourg, France, is a biopharmaceutical company dedicated to the
discovery and development of therapeutic vaccines, immunotherapy
products, and delivery technologies for the treatment of diseases
for which there is no cure or adequate treatment at present, with a
focus on the treatment of cancer. Transgene has five products in
clinical development, two of which are in Phase II clinical trials,
two in Phase I/II and one that has completed Phase I clinical
trial. Transgene's proprietary vector technology platform consists
of adenovirus and poxvirus vector families. DATASOURCE: Transgene
CONTACT: Philippe Poncet, C.F.O. and Investors Relations,
Transgene, +33-3-88-27-91-01; Michael Long, Cohn & Wolfe,
+1-415-365-8523, for Transgene; Tiphaine Hecketsweiler, Image 7,
+33-1-53-70-74-70, for Transgene Web site: http://www.transgene.fr/
Copyright